Elicera Therapeutics AB (publ) 8E8.F Stock
Elicera Therapeutics AB (publ) Price Chart
Elicera Therapeutics AB (publ) 8E8.F Financial and Trading Overview
| Elicera Therapeutics AB (publ) stock price | 0.07 EUR |
| Previous Close | 0.23 EUR |
| Open | 0.23 EUR |
| Bid | 0.23 EUR x N/A |
| Ask | 0.28 EUR x N/A |
| Day's Range | 0.23 - 0.23 EUR |
| 52 Week Range | 0.22 - 0.43 EUR |
| Volume | 4.6K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 4.99M EUR |
| Beta (5Y Monthly) | 0.485777 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
8E8.F Valuation Measures
| Enterprise Value | 4.47M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Elicera Therapeutics AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.485777 |
| 52-Week Change | -30.24% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.43 EUR |
| 52 Week Low | 0.22 EUR |
| 50-Day Moving Average | 0.27 EUR |
| 200-Day Moving Average | 0.31 EUR |
8E8.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 19.78M |
| Float | 9.08M |
| Short Ratio | N/A |
| % Held by Insiders | 62.87% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.66% |
| Return on Equity (ttm) | -43.45% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 276.69% |
| Gross Profit (ttm) | 1.28M EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.256 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Elicera Therapeutics AB (publ)
| Country | Germany |
| State | N/A |
| City | Gothenburg |
| Address | World Trade Centre Gothenburg |
| ZIP | 412 51 |
| Phone | 46 7 03 31 90 51 |
| Website | https://www.elicera.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Q&A For Elicera Therapeutics AB (publ) Stock
What is a current 8E8.F stock price?
Elicera Therapeutics AB (publ) 8E8.F stock price today per share is 0.07 EUR.
How to purchase Elicera Therapeutics AB (publ) stock?
You can buy 8E8.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Elicera Therapeutics AB (publ)?
The stock symbol or ticker of Elicera Therapeutics AB (publ) is 8E8.F.
Which industry does the Elicera Therapeutics AB (publ) company belong to?
The Elicera Therapeutics AB (publ) industry is Biotechnology.
How many shares does Elicera Therapeutics AB (publ) have in circulation?
The max supply of Elicera Therapeutics AB (publ) shares is 49.33M.
What is Elicera Therapeutics AB (publ) Price to Earnings Ratio (PE Ratio)?
Elicera Therapeutics AB (publ) PE Ratio is now.
What was Elicera Therapeutics AB (publ) earnings per share over the trailing 12 months (TTM)?
Elicera Therapeutics AB (publ) EPS is -0.07 EUR over the trailing 12 months.
Which sector does the Elicera Therapeutics AB (publ) company belong to?
The Elicera Therapeutics AB (publ) sector is Healthcare.